-
Beijing Honglin Pharm.
-
GoeGoe Honglin BioPharm. (Jiangsu)
GoeGoe Honglin Pharmaceutical Co. is a technology-driven pharmaceutical company specializing in the development and manufacturing of high-quality generic medicines. Guided by a commitment to quality, innovation, and patient care, we leverage advanced pharmaceutical technologies and manufacturing expertise across a diverse portfolio of medicines to improve access to reliable and affordable treatments.
GoeGoe Honglin Pharmaceutical Co. is a technology-driven pharmaceutical company specializing in the development and manufacturing of high-quality generic medicines. Guided by a commitment to quality, innovation, and patient care, we leverage advanced pharmaceutical technologies and manufacturing expertise across a diverse portfolio of medicines to improve access to reliable and affordable treatments.
Building upon the foundational principles of ALZA's OROS technology, GoeGoe Honglin applies advanced controlled-release formulation expertise to develop reliable medicines that support consistent treatment and long-term patient care.
Our multidisciplinary team of experts leads the development of high-barrier generic formulations. We hold five proprietary patents in controlled-release technologies, safeguarding our breakthroughs in sustained-release pellets, enteric-coated systems, and bilayer osmotic tablets.
GoeGoe Honglin integrates internationally sourced equipment and raw materials with advanced production technologies to maintain consistent product quality. Our standardized facilities in Beijing and Jiangsu support scalable production and reliable supply.
Address : Yanqi Economic Development Area, Huairou District, Beijing, China 101407
Telephone : +86-10-61669960
Fax : +86-10-61669841/43
E-mail : blfy@osihl.com
No. 111 Yangtze River Road, Zhenjiang Economic and Technological Development Zone, Zhenjiang City, Jiangsu Province, China 212132
Telephone : +86-511-88891188
Fax : +86-511-88908008

Nifedipine Controlled-release Tablets
Nifedipine
1. Vasospastic Angina
2. Chronic Stable Angina (Classical Effort-Associated Angina)
3. Hypertension
Included in the National Essential Medicines List and classified as Category A of National Medical Insurance; it boasts a large market scale.
Adopts a double-layer osmotic pump controlled-release formulation and is supported by national patent technology, enabling stable blood pressure reduction, minimal side effects, and greater convenience with once-daily administration.
Produced using European and American imported equipment, featuring mature manufacturing processes, large batch production, high product quality, and sufficient production capacity.
Has passed the Consistency Evaluation of Generic Drugs, ensuring its quality and therapeutic effect are consistent with the original research drug.